98 completed, 24 terminated, 12 recruiting, 10 active not recruiting. 86 Phase 2, 25 Phase 3, 17 Phase 1, 8 Phase 4, 1 Early Phase 1.
Follow ofatumumab: new trials by email Literature Review of ofatumumab trials Research Report on ofatumumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) - Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy | Phase 3 | Recruiting | University Hospital, Montpellier | 250 | 2026-06-15 | 2026-06-23 |
| Switch to Ofatumumab and Level of Immunoglobulins ofatumumab - Multiple Sclerosis | Not yet recruiting | University Hospital, Lille | 115 | 2026-06-01 | 2026-07-10 | |
| An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS). NK042, ofatumumab - Multiple Sclerosis | Early Phase 1 | Not yet recruiting | The Affiliated Hospital of Xuzhou Medical University | 20 | 2026-05-01 | 2026-04-22 |
| Immune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy monoclonal CD-20 antibodies, No Drug, Other treatment - Multiple Sclerosis, Pregnancy | Not yet recruiting | Region Stockholm | 111 | 2026-02-01 | 2025-11-25 | |
| Ofatumumab in Treatment-Refractory¬ Narcolepsy Type 1 ofatumumab 20mg - Narcolepsy Type 1 (NT1) | Phase 1 / Phase 2 | Recruiting | Xijing Hospital | 20 | 2025-10-01 | 2026-10-13 |
| B-cell Depletion in Offspring to Women With MS Under Immunomodulatory Treatment Anti-CD20 Monoclonal Antibody - Multiple Sclerosis, B-Cell Deficiency | Unknown | Region Stockholm | 111 | 2025-06-01 | 2024-12-02 | |
| Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study Ofatumumab - Relapsing Multiple Sclerosis (RMS) | Recruiting | Novartis Pharmaceuticals | 160 | 2024-12-10 | 2026-06-11 | |
| Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis Ofatumumab combined with daratumumab, Ofatumumab, Repeated intravenous immunoglobulin/plasma exchange therapy - Anti-N-Methyl-D-Aspartate Receptor Encephalitis | Phase 3 | Recruiting | The First People's Hospital of Changzhou | 200 | 2024-11-08 | 2026-06-09 |
| A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis ofatumumab, DMT category 1 - Multiple Sclerosis | Active not recruiting | Novartis Pharmaceuticals | 519 | 2024-10-23 | 2026-10-06 | |
| ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients Ofatumumab - Multiple Sclerosis, Relapsing-Remitting | Active not recruiting | Novartis Pharmaceuticals | 379 | 2024-07-30 | 2026-04-13 | |
| A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice ofatumumab - Relapsing Forms of Multiple Sclerosis | Completed | Novartis Pharmaceuticals | 310 | 2024-02-26 | 2025-12-29 | |
| Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France ofatumumab - Multiple Sclerosis (MS) | Active not recruiting | Novartis Pharmaceuticals | 302 | 2023-12-21 | 2026-04-29 | |
| WOE of Anti-CD20 Therapies ocrelizumab, ofatumumab - Multiple Sclerosis | Completed | Novartis Pharmaceuticals | 157 | 2023-12-04 | 2025-07-11 | |
| Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels Ofatumumab - Multiple Sclerosis | Recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 80 | 2023-12-01 | 2026-01-20 | |
| Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study Ofatumumab - Relapsing Multiple Sclerosis | Recruiting | Novartis Pharmaceuticals | 174 | 2023-11-27 | 2026-07-07 | |
| Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years Ofatumumab - Relapsing Multiple Sclerosis | Active not recruiting | Novartis Pharmaceuticals | 106 | 2023-07-10 | 2025-12-30 | |
| Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab Ofatumumab - Multiple Sclerosis, Tomography, Optical Coherence | Enrolling by invitation | Johns Hopkins University | 75 | 2023-05-22 | 2026-06-10 | |
| The 'Wearing Off' Effect of DMT ocrelizumab, natalizumab, ofatumumab - Multiple Sclerosis | Completed | Novartis Pharmaceuticals | 39 | 2023-01-10 | 2023-06-01 | |
| Kesimpta (Ofatumumab) Pregnancy Registry Kesimpta - Multiple Sclerosis, Pregnancy | Recruiting | Novartis Pharmaceuticals | 725 | 2023-01-05 | 2025-01-14 | |
| Characterizing the Use of Ofatumumab in a Real World Setting ofatumumab - Relapsing Multiple Sclerosis | Completed | Novartis Pharmaceuticals | 103 | 2022-12-08 | 2026-07-31 |
Showing 20 of 157. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (46) · Multiple Sclerosis (28) · Lymphoma (15) · Lymphoma, Non-Hodgkin (15) · Leukemia (14) · Leukemia, B-Cell (14) · Recurrence (13) · Lymphoma, Follicular (11) · Multiple Sclerosis, Relapsing-Remitting (10) · Lymphoma, Large B-Cell, Diffuse (7) · Neoplasms (7) · Lymphoma, Mantle-Cell (6) · Bronchiolitis Obliterans Syndrome (5) · Burkitt Lymphoma (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5)
Novartis Pharmaceuticals (41) · GlaxoSmithKline (22) · M.D. Anderson Cancer Center (11) · Gruppo Italiano Malattie EMatologiche dell'Adulto (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · SCRI Development Innovations, LLC (3) · Dana-Farber Cancer Institute (2) · Gilead Sciences (2) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (2) · Istituto Giannina Gaslini (2) · Johns Hopkins University (2) · National Cancer Institute (NCI) (2) · Nevada Cancer Institute (2) · Pharmacyclics LLC. (2) · Region Stockholm (2)
United States (91) · Italy (24) · Spain (22) · Germany (19) · United Kingdom (19) · Belgium (18) · France (18) · Poland (16) · Australia (14) · Czechia (13) · Russia (13) · Austria (11) · Canada (11) · Hungary (10) · Japan (10)
Elias Jabbour (3) · Alessandra Ferrajoli (2) · Celeste Bello, M.D. (2) · Francesca R. Mauro (2) · Gianmarco Ghiggeri, MD (2) · Ian Flinn, MD, PhD (2) · Mark Kirschbaum, MD (2) · Agostino Cortelezzi, MD (1) · Agostino Cortelezzi, Pr. (1) · Alessandro M. Gianni, MD (1) · Alessandro Pulsoni, MD (1) · Alessandro Rambaldi, MD (1)
PMID 24443277, PMID 25103870, PMID 26182309, PMID 35622074, PMID 35787017, PMID 18003886, PMID 18390837, PMID 20194866, PMID 20408846, PMID 21816833, PMID 23692856, PMID 23729801, PMID 23886836, PMID 24032456, PMID 24431228, PMID 24881631, PMID 24925211, PMID 25596264, PMID 25630297, PMID 25645263, PMID 25775024, PMID 25882396, PMID 25964296, PMID 26116658, PMID 26294723, PMID 26377300, PMID 26784000, PMID 26813675, PMID 27214073, PMID 27222473, PMID 27247136, PMID 27389174, PMID 27570087, PMID 27914971, PMID 28041583, PMID 28126927, PMID 28257752, PMID 28314744, PMID 28373262, PMID 28687625, PMID 28751558, PMID 29296805, PMID 29358183, PMID 29470582, PMID 29695594, PMID 30287523, PMID 30322319, PMID 30842083, PMID 30967392, PMID 31073022
2009 (3), P30CA016672 (3), 2008 (1), 2014 (1), 2015 (1), 2019 (1), 2023 (1), N01CM00070 (1), N01CM62207 (1), P30CA015083 (1), P30CA016058 (1), P50CA140158 (1), U01CA076576 (1), U10CA031946 (1), U10CA180821 (1)